Loading patent record…
US 10,092,525 B2
Source-reported patent metadata. Patent status is not a legal opinion or evidence of treatment efficacy.
Bibliographic record
Source abstract
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Patent document
The source abstract is shown above. Open the source document for the complete description, claims, drawings and search report where the publisher provides them.
Unmodified official patent-document facsimile stored by CannabisHub
Open locally preserved patent PDFExact official facsimile · USPTO official patent facsimile; exact reproduction with attributionPublished patent document
Open patent PDFDescription, claims, drawings and source timeline
Description and claims at sourceOfficial published grant, including description and claims
Open official USPTO patent PDFWhen a local copy is available, it is the unchanged official PDF with recorded source rights and checksum. Otherwise the document opens at the originating service.
People and ownership
GW Pharma Ltd
Alice Mead · Geoffrey Guy · Orrin Devinsky · Stephen Wright
Regulatory connection
The medicine name is a regulatory link, not the patent title and not evidence of treatment efficacy.
Standardised links
These versioned links point to exact source text and are navigation candidates, not evidence of efficacy or patent scope.
Sources and rights
CC0 1.0 · source version 2026-10-16
Retrieved 16/10/2026, 13:48:53Verify at sourceLicense not stated · source version 2018-10-09
Retrieved 25/09/2026, 13:30:58Verify at sourceOrganisations & named parties
Source-reported roles. Product and study context does not establish treatment efficacy or corporate ownership.